As an integral part of the CCNE, we propose to create a pre-doctoral and post-doctoral training program in cancer nanomedicine that will: (1) bridge the gap in language and skills between the physical sciences/engineering and cancer biology/oncology communities, (2) contribute to the creation of new knowledge and new technologies, and (3) train a new generation of multidisciplinary scientists and engineers in cancer nanomedicine.
SPECIFIC AIMS Aim 1 (Education/Training). To recruit pre-doctoral students and post-doctoral fellows with backgrounds in the biological sciences, physical sdences, or engineering. Special efforts will be conducted to recruit, retain, and mentor trainees from under-represented groups.
Aim 2 (Education/Training). To train a new generation of mulddisciplinary scientists, engineers, and clinicians in cancer nanomedicine.
Aim 3 (Education/Training). To provide students and fellows the opportunity to conduct research in cancer nanomedicine. Each trainee will be co-mentored by at least one faculty in the physical sciences/engineering and at least one faculty in cancer biology/oncology.
Aim 4 (Education/Training and Outreach). To provide CCNE researchers the opportunity to visit other CCNEs by establishing an exchange program.
Aim 5 (Outreach). Establish a comprehensive set of outreach activities to disseminate the new knowledge and new technologies created in the proposed CCNE to the relevant scientific communities and constituencies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151838-04
Application #
8545558
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
2010-08-25
Project End
2015-07-31
Budget Start
2013-09-13
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$108,197
Indirect Cost
$105,001
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Song, Xiaolei; Yang, Xing; Ray Banerjee, Sangeeta et al. (2015) Anthranilic acid analogs as diamagnetic CEST MRI contrast agents that feature an intramolecular-bond shifted hydrogen. Contrast Media Mol Imaging 10:74-80
Srivastava, Amit K; Bulte, Jeff W M (2014) Seeing stem cells at work in vivo. Stem Cell Rev 10:127-44
Nimmagadda, Sridhar; Pullambhatla, Mrudula; Lisok, Ala et al. (2014) Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochem Biophys Res Commun 443:635-40
Li, Yang; Foss, Catherine A; Pomper, Martin G et al. (2014) Imaging denatured collagen strands in vivo and ex vivo via photo-triggered hybridization of caged collagen mimetic peptides. J Vis Exp :e51052
Bulte, Jeff W M; Schmieder, Anne H; Keupp, Jochen et al. (2014) MR cholangiography demonstrates unsuspected rapid biliary clearance of nanoparticles in rodents: implications for clinical translation. Nanomedicine 10:1385-8
Bhatnagar, Akrita; Wang, Yuchuan; Mease, Ronnie C et al. (2014) AEG-1 promoter-mediated imaging of prostate cancer. Cancer Res 74:5772-81
Das, Samarjit; Bedja, Djahida; Campbell, Nathaniel et al. (2014) miR-181c regulates the mitochondrial genome, bioenergetics, and propensity for heart failure in vivo. PLoS One 9:e96820
Williford, John-Michael; Wu, Juan; Ren, Yong et al. (2014) Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng 16:347-70
Shallal, Hassan M; Minn, Il; Banerjee, Sangeeta R et al. (2014) Heterobivalent agents targeting PSMA and integrin-?v?3. Bioconjug Chem 25:393-405
Yang, Xing; Yadav, Nirbhay N; Song, Xiaolei et al. (2014) Tuning phenols with Intra-Molecular bond Shifted HYdrogens (IM-SHY) as diaCEST MRI contrast agents. Chemistry 20:15824-32

Showing the most recent 10 out of 56 publications